ReviewCureus2025
A Systematic Review of the Clinical Features, Management, and Outcomes in Urethral Squamous Cell Carcinoma.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary urethral squamous cell carcinoma (SCC) is a rare and aggressive malignancy, accounting for a minority of genitourinary cancers but presenting significant diagnostic and therapeutic challenges. Due to its rarity, limited data exists to guide standardized management. We aim to systematically review the available literature on urethral SCC, with a focus on epidemiology, clinical presentation, histological characteristics, treatment modalities, and patient outcomes. A comprehensive systematic search of PubMed was conducted for studies published between January 1995 and December 2025, with data extraction performed in accordance with PRISMA guidelines. The inclusion criteria encompassed studies involving patients with histologically confirmed urethral SCC. Retrospective studies and case series/reports were included due to the absence of prospective trials. Primary outcomes included overall survival and disease-specific survival, while secondary outcomes encompassed recurrence rates, treatment-related complications, and quality of life. A total of 27 studies (15 retrospective and 12 case reports/series) were included, representing 2,917 male and 1,292 female patients. The majority of patients were over 60 years of age. The most common presenting symptoms included lower urinary tract obstruction, hematuria, and pelvic mass. High-grade tumors (Grade 3 and 4) were most frequently observed. Treatment modalities varied widely and included transurethral resection, urethrectomy, chemotherapy, and radiotherapy, often in combination. Recurrence was observed in 139 patients, while metastasis was reported in 51. The reported 5- to 10-year survival rates ranged from 30% to 60%. Urethral SCC is a highly aggressive and understudied malignancy with heterogeneous clinical features and treatment practices. The findings underscore the urgent need for standardized staging criteria, prospective multicenter studies, and consensus-driven treatment guidelines. Improved recognition and tailored therapeutic strategies are critical to enhancing outcomes in this rare but impactful cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.